Who is sponsoring NCT05841342?

NCT05841342 is sponsored by Beijing Friendship Hospital.

What drugs are being tested in NCT05841342?

Interventions in NCT05841342: No intervention.

What condition does NCT05841342 study?

NCT05841342 studies Secondary Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection.

Is NCT05841342 still recruiting?

NCT05841342 is currently status unknown. Last updated 3 May 2023.

Last reviewed 2023-05-03 · How we verify

NCT05841342

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients

Status unknown Last updated 3 May 2023

What this trial tests

trial testing No intervention in Secondary Hemophagocytic Lymphohistiocytosis in 128 participants. Status unknown.

Timeline

1 October 2022

Primary endpoint
30 April 2024

30 June 2024

Quick facts

Lead sponsor	Beijing Friendship Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	128
Start date	1 October 2022
Primary completion	30 April 2024
Estimated completion	30 June 2024
Sites	1 location across China

Drugs / interventions tested

No intervention

Conditions studied

Secondary Hemophagocytic Lymphohistiocytosis — all drugs for Secondary Hemophagocytic Lymphohistiocytosis →
Chronic Active Epstein-Barr Virus Infection — all drugs for Chronic Active Epstein-Barr Virus Infection →

Sponsor

Beijing Friendship Hospital

Who can join

Adults 2 to 80, any sex, with Secondary Hemophagocytic Lymphohistiocytosis or Chronic Active Epstein-Barr Virus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective case-control study aims to evaluate the immune function and find PD-1 antibody efficacy predictors on Chronic Active Epstein-Barr Virus Infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis by detecting lymphocyte subsets proportions in peripheral blood mononuclear cells and the positive proportion of PD-1, PD-L1 and other indicators in each lymphocyte subsets in healthy people and patients using flow cytometry before and after the initial PD-1 therapy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Role of rapidly evolving immunotherapy in chronic active Epstein-Barr virus disease.
Yan S, Ming X, Zhu X, Xiao Y. · · 2024 · cited 5× · PMID 39691713 · DOI 10.3389/fimmu.2024.1451977
Lymphocytes in Patients with Chronic Active Epstein-Barr Virus Disease Exhibited Elevated PD-1/PD-L1 Expression and a Prevailing Th2 Immune Response.
Sun K, Wu C, Kong Q, Hu J, et al · · 2024 · cited 1× · PMID 38882461 · DOI 10.4084/mjhid.2024.037

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting

Other recruiting trials for Secondary Hemophagocytic Lymphohistiocytosis

Currently open trials in the same condition.

NCT06339177 — Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study · recruiting

Other Beijing Friendship Hospital trials

Trials by the same sponsor.

NCT07453862 — Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety · Phase 1 · recruiting
NCT07397442 — Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07393048 — Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant The · recruiting
NCT07441850 — Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy · NA · recruiting
NCT07369739 — Golidocitinib Combined With Selinexor for CAEBVD · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05841342 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Friendship Hospital
Last refreshed: 3 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05841342.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing